Nurix Therapeutics (NRIX) has drawn investor attention after two key events. The company reported a new Phase 3 trial for its BTK degrader bexobrutideg and a separate US$10 million milestone payment from collaborator Sanofi.

Against this backdrop, Nurix Therapeutics’ recent clinical milestones and collaboration progress have coincided with strong momentum, with a 30 day share price return of 17.52% and a 1 year total shareholder return of 166.24%. This suggests improving sentiment toward longer term prospects.

If you are weighing Nurix Therapeutics alongside other potential growth stories in healthcare, this can be a good moment to scan for similar opportunities in advanced drug discovery using the 40 healthcare AI stocks

Nurix Therapeutics shares now sit around US$27.17, which is below the average analyst target of US$33.50. After such a strong 12 month run, is that discount signaling opportunity or sensible caution given current losses?

Preferred Price-to-Book of 7x for Nurix Therapeutics: Is it justified?

Nrix trades on a P/B of 7x against the latest close of $27.17, which looks rich versus the wider US Biotechs industry but cheaper than its selected peers.

The P/B ratio compares a company’s market value with its book value, which is the accounting value of net assets on the balance sheet. For clinical stage biopharma groups like Nurix Therapeutics, investors often focus less on current revenues and more on the potential value of the pipeline and existing collaboration agreements when assigning this multiple.

On one side, Nurix Therapeutics looks expensive compared with the broader US Biotechs industry, where the average P/B sits at 2.4x. On the other side, the stock is priced below its more closely matched peer group, which averages a much higher 13.4x. That split suggests the market is pricing Nurix somewhere between the sector base rate and the higher valuations of closer comparables, rather than at a clear bargain or clear excess against either benchmark.

Result: Price-to-book of 7x (ABOUT RIGHT)

However, you also need to weigh ongoing losses of US$341.351m and declining annual revenue growth, since any setback in Nurix Therapeutics trials could quickly hit sentiment.

Next Steps

With sentiment on Nurix Therapeutics finely balanced between its recent progress and ongoing risks, it can help to move quickly and review the underlying data for yourself. To see how current concerns and potential rewards compare side by side, start with the 1 key reward and 2 important warning signs

Looking for more Nurix Therapeutics style investment ideas?

Do not stop with Nurix Therapeutics. Use focused stock lists to spot other opportunities that match your goals and keep your research edge sharp.

• Target potential value opportunities by reviewing companies filtered for quality and pricing using the 53 high quality undervalued stocks
• Prioritise strength by checking businesses screened for resilient finances with the solid balance sheet and fundamentals stocks screener (50 results)
• Hunt for future leaders before they become widely followed by using the screener containing 19 high quality undiscovered gems

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.